Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies

Abstract

Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases.

1 . A compound having a formula: 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt thereof, where A 1  and B 1  are each independently selected from halogen, pseudohalo, nitro,  + NH 3 , SO 3 H, carboxy and haloalkyl; and
 t and v are each independently 1 to 3. 
 
   
   
       2 . The compound of  claim 1 , wherein the compound has a formula selected from: 
     
       
         
         
             
             
         
       
     
   
   
       3 . The compound of  claim 1 , wherein the compound has a formula selected from: 
     N-(3,4-dihydroxyphenyl)-2-fluoro-3,4-dihydroxybenzamide, 
     N-(3,4-dihydroxyphenyl)-2-fluoro-4,5-dihydroxybenzamide, 
     N-(3,4-dihydroxyphenyl)-3-fluoro-4,5-dihydroxybenzamide, 
     N-(3-fluoro-4,5-dihydroxyphenyl)-3,4-dihydroxybenzamide, 
     N-(2-fluoro-4,5-dihydroxyphenyl)-3,4-dihydroxybenzamide, and 
     N-(2-fluoro-3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide. 
   
   
       4 . The compound of  claim 1 , wherein A 1  and B 1  are each independently selected from F, Cl, Br, I, cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, and azide, 
   
   
       5 . A pharmaceutical composition comprising the compound of  claim 1  or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
   
   
       6 . An article of manufacture, comprising packaging material, the compound of  claim 1 , or a pharmaceutically acceptable salt thereof, contained within packaging material, which is used for treating the formation, deposition, accumulation, or persistence of amyloid protein, and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treating the formation, deposition, accumulation, or persistence of amyloid protein. 
   
   
       7 . A method of treating the formation, deposition, accumulation, or persistence of amyloid protein, comprising administering an effective amount of the compound of  claim 1 . 
   
   
       8 . The method of  claim 7 , where the amyloid protein is Aβamyloid fibrils. 
   
   
       9 . The method of  claim 7 , where the amyloid protein is IAPP amyloid fibrils. 
   
   
       10 . The method of  claim 7 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day. 
   
   
       11 . The method of  claim 7 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day. 
   
   
       12 . The method of  claim 7 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day. 
   
   
       13 . An article of manufacture, comprising packaging material, the compound of  claim 1 , or a pharmaceutically acceptable salt thereof, contained within packaging material, which is used for treating the formation, deposition, accumulation, or persistence of α-synuclein protein, and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treating the formation, deposition, accumulation, or persistence of α-synuclein protein. 
   
   
       14 . A method of treating the formation, deposition, accumulation, or persistence of α-synuclein protein, comprising administering an effective amount of the compound of  claim 1 . 
   
   
       15 . The method of  claim 14 , where the α-synuclein proteins are α-synuclein fibrils. 
   
   
       16 . The method of  claim 14 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day. 
   
   
       17 . The method of  claim 14 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day. 
   
   
       18 . The method of  claim 14 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day. 
   
   
       19 . The compound of  claim 1  where A 1  or B 1  is  18 F. 
   
   
       20 . An amyloid imaging agent comprising the compound of  claim 1  where A 1  or B 1  is  18 F. 
   
   
       21 . A method of in vivo imaging of amyloid deposits, comprising introducing into a mammal a detectable quantity of the compound of  claim 1  which has been radiolabeled; allowing sufficient time for the labeled compound to become associated with amyloid deposits and detecting the labeled compound associated with one or more amyloid deposits. 
   
   
       22 . The method of  claim 21  wherein the step of detecting the labeled compound is by positron emission tomography or single photon emission computed tomography. 
   
   
       23 . An amyloid diagnostic agent comprising the compound of  claim 1  wherein A 1  or B 1  is  18 F. 
   
   
       24 . A method of in vivo diagnosis of Alzheimer's disease, comprising introducing into a mammal a detectable quantity of the compound of  claim 1  which has been radiolabeled, allowing sufficient time for the labeled compound to become associated with amyloid deposits and detecting the labeled compound associated with one or more amyloid deposits. 
   
   
       25 . The method of  claim 24  wherein the step of detecting the labeled compound is by positron emission tomography or single photon emission computed tomography. 
   
   
       26 . An α-synuclein imaging agent comprising the compound of  claim 1  wherein A 1  or B 1  is  18 F. 
   
   
       27 . A method of in vivo imaging of α-synuclein deposits, comprising introducing into a mammal a detectable quantity of the compound of  claim 1  which has been radiolabeled; allowing sufficient time for the labeled compound to become associated with α-synuclein deposits; and detecting the labeled compound associated with one or more α-synuclein deposits. 
   
   
       28 . The method of  claim 27  wherein the step of detecting the labeled compound is by positron emission tomography or single photon emission computed tomography. 
   
   
       29 . An a synuclein diagnostic agent comprising the compound of  claim 1  wherein A 1  or B 1  is  18 F. 
   
   
       30 . A method of in vivo diagnosis of Parkinson's disease, comprising introducing into a mammal a detectable quantity of the compound of  claim 1  which has been radiolabeled, allowing sufficient time for the labeled compound to become associated with Lewy body deposits and detecting the labeled compound associated with one or more Lewy body deposits. 
   
   
       31 . The method of  claim 30  wherein the step of detecting the labeled compound is by single photon emission computed tomography or single photon emission computed tomography.